Phase II Study of BCMA CAR-T Therapy in Newly Diagnosed Multiple Myeloma: CAREMM-001

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Feb 2026. The item focuses on Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). Review the original article for the full source wording and details.